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A B S T R A C T
Treatment of high-risk childhood neuroblastoma is a clinical challenge which has been hampered by a
lack of reliable neuroblastoma mouse models for preclinical drug testing. We have previously estab-
lished invasive and metastasising patient-derived orthotopic xenografts (PDXs) from high-risk
neuroblastomas that retained the genotypes and phenotypes of patient tumours. Given the important
role of the tumour microenvironment in tumour progression, metastasis, and treatment responses, here
we analysed the tumour microenvironment of ﬁve neuroblastoma PDXs in detail. The PDXs resembled
their parent tumours and retained important stromal hallmarks of aggressive lesions including rich blood
and lymphatic vascularisation, pericyte coverage, high numbers of cancer-associated ﬁbroblasts, tumour-
associated macrophages, and extracellular matrix components. Patient-derived tumour endothelial cells
occasionally formed blood vessels in PDXs; however, tumour stroma was, overall, of murine origin. Lym-
phoid cells and lymphatic endothelial cells were found in athymic nude mice but not in NSG mice; thus,
the choice of mouse strain dictates tumour microenvironmental components. The murine tumour mi-
croenvironment of orthotopic neuroblastoma PDXs reﬂects important hallmarks of aggressive andmetastatic
clinical neuroblastomas. Neuroblastoma PDXs are clinically relevant models for preclinical drug testing.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
The high attrition of novel agents hampers oncology drug de-
velopment [1,2], in part because conventional preclinical cancer
models do not fully resemble the clinical disease and thus have low
predictive power [2–4]. Patient-derived xenografts (PDXs) have re-
cently attracted interest because established PDXs faithfully reﬂect
the genetic and histopathological characteristics of human disease.
As a consequence, PDXs better predict clinical outcomes than con-
ventional cell line-derived xenografts, and PDXs have emerged as
a promising strategy to personalise patient selection and treat-
ment and for investigating themechanisms of therapeutic resistance
[3–6].
Neuroblastoma, a childhood tumour of the developing sympa-
thetic nervous system, remains a therapeutic challenge. Patientswith
high-risk tumours often have a poor prognosis despite treatment
with dose-intensive chemotherapy, surgery, radiotherapy, and/or im-
munotherapy [7,8].Werecently establishedorthotopicneuroblastoma
PDXs by implanting undissociated high-risk neuroblastoma frag-
ments into the para-adrenal space of immunodeﬁcient NOD/SCID/
gamma(c)(null) (NSG)mice [9]. The neuroblastoma PDXs accurately
recapitulated the genomic and phenotypic features of the corre-
sponding patient tumours and displayed widespread and robust
metastases to lungs, liver, and bone marrow. Furthermore, we es-
tablished in vitro cultures derived from neuroblastoma PDXs, and
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these cells expressed neuroblastoma markers and retained
tumourigenic and metastatic capacity in vivo after orthotopic in-
jection into mice [9].
The undissociated tumour fragments used to establish PDX
models contain both neuroblastoma cells and components of the
tumour microenvironment (TME). The TME plays an important role
in neuroblastoma progression and metastasis [10], tumour treat-
ment responses, and therapeutic resistance [11,12]. Recent studies
suggest that TME components can induce stem cell-like features in
tumour cells [13,14]. The TME includes immune cells, cancer-
associated ﬁbroblasts (CAFs), blood vessels, lymphatic vessels,
pericytes, and extracellular matrix (ECM) [15]. Aggressive neuro-
blastomas are typically highly vascularised with blood [16] and
lymphatic [17] vessels, contain high numbers of tumour-associated
macrophages (TAMs) [18,19] and CAFs [20], and are Schwannian
stroma-poor tumours [21,22]. Furthermore, neuroblastomas contain
lymphoid immune cells [19,23] and ECM components [24]. However,
the extent to which co-engrafted human tumour stroma survives
and contributes to neuroblastoma PDX growth and how murine
stroma participates in this process are unknown. Therefore, and given
the signiﬁcance of the TME in neuroblastoma progression [10], we
performed a comprehensive analysis of human and mouse stroma
in neuroblastoma PDXs. Our aims were to establish: (i) whether co-
engrafted patient-derived tumour stromal cells persist in
neuroblastoma PDXs and (ii) examine the extent to which mouse-
derived stroma replaces and reﬂects the TME in clinical neuro-
blastoma specimens.
Here we report that previously established [9] and two new PDXs
(one of which lacks MYCN ampliﬁcation) recapitulate clinically im-
portant TME hallmarks of the original neuroblastomas from patients.
The rich vascularisation, pericyte coverage, TAM inﬁltration, and CAF
and ECM composition resembled that of aggressive patient tumours.
Patient-derived tumour endothelial cells were able to form blood
vessels in PDXs, although tumour stroma was predominantly re-
placed with murine stroma. Little is known about differences in TME
in different immunodeﬁcientmouse strains.We show that the choice
of mouse strain dictated the presence of TME lymphoid immune
cells and lymphatic endothelial cells. Furthermore, spontaneous me-
tastases from orthotopic neuroblastoma PDXs also contained TME
components, albeit to a lesser extent than the primary tumours at
the adrenal site. These results further support the use of neuro-
blastoma PDXs as clinically relevant models for drug testing in
aggressive and metastatic neuroblastoma.
Materials & methods
Processing of viable neuroblastoma samples
Primary viable neuroblastoma samples were obtained from surgical neuroblas-
toma specimens. Intact tumour explants (approximately 2 × 2 × 2 mm) were
cryopreserved in 50% foetal bovine serum (FBS), 40% DMEM high glucose cell media
(Corning, New York, USA) and 10% dimethyl sulfoxide (DMSO) by stepwise cooling
using CoolCell (BioCision, Larkspur, CA, USA) and stored at −80 °C. Tumour ex-
plants were thawed immediately before implantation. The Regional Ethical Review
Board at Lund University (Dnr. 2011/289) and the Ethical Committee of the Clini-
cal Hospital of Valencia and the ISCIII (reference: B0000339 26/11/2012) approved
the study. Written informed consent was obtained from patients.
Animal procedures
Animal procedures are described elsewhere [9]. Brieﬂy, four- to six-week-old
female or male NSG mice were purchased from Charles River Laboratories (Wilm-
ington, MA, USA). Athymic nude mice were purchased from Taconic Biosciences Inc.
(Hudson, NY, USA). Mice were housed under pathogen-free conditions and re-
ceived autoclaved water and food. Mice were anaesthetised by 2.5% isoﬂurane
inhalation. Intact patient-derived tumour fragments were incubated in Matrigel (BD
Biosciences, San Jose, USA) for a minimum of 20 min at 4 °C before being placed in
the para-adrenal space and immediately covered with Matrigel. PDX-derived cul-
tured cells (1 × 106 cells) were injected into the adrenal gland of athymic nude mice
(n = 5). Mice were sacriﬁced immediately when they exhibited symptoms of tumour
growth. All animal procedures followed the guidelines set by theMalmö-Lund Ethical
Committee for the use of laboratory animals and were conducted in accordance with
the European Union directive on animal rights.
Immunohistochemistry (IHC) and histochemistry
Xenograft tumours and mice organs were formalin-ﬁxed, embedded in paraf-
ﬁn, and 4 μm tissue sections were cut and analysed using single-marker IHC. A list
of antibodies and their working dilutions is shown in Supplementary Table S1. Images
were acquired using an Olympus BX63 microscope equipped with UPlanSApo ob-
jective lenses and a DP80 camera, and images were analysed using the cellSens
Dimension imaging software (Olympus Life Sciences, Shinjuku, Japan). Slightly modi-
ﬁed Gomori staining was used to detect reticulin ﬁbres, Masson’s trichome was used
to visualise collagen type I ﬁbres, and glycosaminoglycans were detected with Alcian
blue at pH 2.5. Sections from all PDX models (n = 5) were analysed for each marker
unless otherwise stated. Eight representative regions from each IHC slide (n = 1 per
patient tumour/PDX) were chosen for manual quantitative analysis using cellSens
Dimension. Average cell numbers were calculated for each slide and presented as
the number of cells per mm2. A quantitative analysis was performed for each ECM
component in patient tumours and PDXs using Image-Pro Plus 6.0 (Media Cyber-
netics, Inc., Silver Spring, MD, USA).
Multi-marker IHC staining and generation of composite images
Primary antibodies were sequentially applied to the tissue. Brieﬂy, 2 μm thick
paraﬃn-embedded tumour sections were subjected to heat-induced epitope re-
trieval (HIER) in a pre-treatment module (PT-link, Dako Cytomation, Glostrup,
Denmark) with Tris buffer (pH 6) before IHC staining at room temperature with an
automated IHC robot (AutostainerPlus, Dako). Sections were sequentially blocked
with endogenous enzyme block (EnVision™ FLEX Peroxidase-Blocking Reagent, Dako)
for 10 min and serum-free protein block (Dako) for 10 min before incubation with
the ﬁrst primary antibodies (Supplementary Table S2) for 60min. Next, sections were
incubated with secondary antibodies for 30 min, followed by incubation with stan-
dard HRP chromogen substrate for 10 min and counterstaining with Mayer’s
haematoxylin. The tissue sections were then digitalised using an Olympus VS-120
virtual slide microscope (Olympus). The procedure was then repeated for the other
primary antibodies (Supplementary Table S2) and the tissue sections were digitalised
after each staining cycle. Finally, the new positive chromogen staining for eachmarker
was segmented out by computerised image analysis and combined into a multi-
composite marker image. Cell numbers are presented as counts.
Single nucleotide polymorphism (SNP) analysis
Patient tumours and PDXs were snap-frozen and stored at −80 °C for SNP array
analysis. Brieﬂy, DNAwas extracted from the cells and tissues using the DNeasy Blood
and Tissue Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instruc-
tions. The Affymetrix CytoScan HD platform was used for SNP array analysis as
described elsewhere [9].
Results
Establishing novel neuroblastoma patient-derived orthotopic
xenografts
Wepreviously reported threemetastasising neuroblastoma PDXs
(PDXs #1–3) in NSG mice 59–102 days after tumour implantation
[9]. Here we show successful engraftment of two additional neu-
roblastoma orthotopic PDXs (PDX #4–5). Tumour tissue for PDX #4
was obtained from a three-year-old child diagnosedwith INSS stage
III neuroblastomawho underwent surgery following chemotherapy.
The SNP copy number proﬁle (most importantly MYCN ampliﬁca-
tion and 17q gain; Supplementary Fig. S1A) and the neuroblastoma
marker pattern (CD56/NCAM, tyrosine hydroxylase, chromogranin
A, and synaptophysin; Supplementary Fig. S1B) demonstrated that
the PDX retains clinically important molecular features of the cor-
responding patient tumour. We further used NCAM IHC to detect
metastatic spread todistantorgans. Therewerea fewmicrometastases
in the lungs and liver (data not shown) but no evidence of
macrometastatic disease and no tumour cells in the bone marrow.
These ﬁndings were very similar to the clinical proﬁle of the cor-
responding stage III patient, in whom no overt distant metastases
were found. Themetastatic behaviour of PDX#4was different from
that of the previously established stage IV tumour-derived PDXs,
which showed robust distant metastatic spread [9].
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Tumour tissue for PDX #5 was obtained from a three-year-old
child with INSS stage IV neuroblastoma that harboured 1p del(e-
tion), 17q gain, and other chromosomal changes including 1pq gain,
2p gain, 4p del, complex chromothripsis-like structural aberra-
tions on chromosome 5, 6p gain, 9pq del, 14q del, and 18q gain but
no MYCN ampliﬁcation (Supplementary Fig. S2A). Most of the chro-
mosomal aberrations, including 1p del and 17q gain, were retained
in PDX #5 (Supplementary Fig. S2A). There were a few genetic dif-
ferences between the patient sample and the PDX including 8q del
in the PDX (Supplementary Fig. S2A). PDX #5 also retained the ex-
pression of neuroblastoma markers CD56/NCAM, tyrosine
hydroxylase, chromogranin A, and synaptophysin (Supplementary
Fig. S2B) and displayed signiﬁcant metastatic spread to lungs and
liver (Supplementary Fig. S2C), but there was no evidence of bone
marrow involvement. PDX #5 represents the ﬁrst non-MYCN am-
pliﬁed metastatic neuroblastoma PDX derived from a high-stage
tumour.
Immune cell distribution in neuroblastoma PDXs
We next investigated neuroblastoma TME hallmarks in the ﬁve
PDXs. The TME was assessed in PDXs established by implantation
of patient-derived undissociated tumour pieces unless otherwise
stated.
We ﬁrst examined the intratumoural distribution of immune cells.
Mouse F4/80-expressing TAMs inﬁltrated all ﬁve neuroblastoma PDXs
(Supplementary Table S3A). TAMs were distributed either as cohe-
sive cell clusters in stromal regions or as single scattered cells located
in the perivascular niche (Fig. 1A). As expected, there was no F4/
80 positivity in patient samples (data not shown). The human-
speciﬁc monocyte/macrophage marker CD68 was used to detect
human TAMs. CD68+ TAMs were found in patient samples, often
in the perivascular niche (Fig. 1B), but PDXs were negative for these
cells (data not shown).
We next examined if human lymphoid cells co-engraft in neu-
roblastoma PDXs established by implantation of undissociated
tumour fragments into NSG mice. Human-speciﬁc CD45-positive
lymphoid cells were found in human tonsil tissue (used as a pos-
itive control, data not shown) and in patient samples (Fig. 1C). There
was no evidence of human CD45-expressing lymphoid cells in PDXs
(Fig. 1D) or in the spleens of mice carrying PDXs (data not shown).
However, mouse-speciﬁc anti-CD45 antibodies detected lym-
phoid cells in tumours established by orthotopic injection of cultured
PDX-derived cells into athymic nude mice (Fig. 1E, Supplementary
Table S3A).
Mouse CAFs inﬁltrate PDXs
Staining with an anti-vimentin mouse/human antibody re-
vealed large numbers of positive cells in all ﬁve PDXs (Fig. 2A). These
cells had a spindle-shaped morphology and were distributed either
as single scattered cells interspersed between tumour cells or as
cohesive clusters in thick bands of ﬁbrous stroma, consistent with
CAFs. We next examined if co-engrafted human CAFs survive in neu-
roblastoma PDXs using a human-speciﬁc anti-vimentin antibody.
Patient samples served as positive controls (Fig. 2B). Analysis of con-
secutive PDX sections revealed several areas containing large
numbers of mouse/human vimentin-positive cells co-expressing
α-smooth muscle actin (αSMA) and lacking expression of human-
speciﬁc vimentin (Fig. 2C). Quantitative data are presented in
Supplementary Table S3A.We concluded that mouse but not human
CAFs contribute to the stromal compartment of neuroblastoma PDXs.
Aggressive neuroblastomas are typically Schwannian stroma-
poor tumours. Antibodies targeting human and mouse S-100β and
mouse myelin revealed no evidence of S-100β- or mouse myelin-
positive cells in neuroblastoma PDXs.
Neuroblastoma PDXs reﬂect the angiogenic proﬁle of patient tumours
PDXs #1–5 were vascularised and contained numerous mouse
CD34 (moCD34)-expressing endothelial cells (Fig. 3A, Supplementary
Table S3A). A human-speciﬁc CD31 (huCD31) antibody was used to
detect human-derived endothelial cells. As expected, therewere large
numbers of huCD31+ endothelial cells in patient samples (Fig. 3B)
Fig. 1. Distribution of immune cells in neuroblastoma PDXs. F4/80-expressing
mouse tumour-associated macrophages (TAMs) in neuroblastoma PDXs located in
cohesive clusters or the perivascular niche, exempliﬁed by PDX #1 (A). CD68-
positive human TAMs in the perivascular niche of a patient sample (B). Human CD45+
lymphoid cells in a patient sample (C). Lack of human CD45-expressing cells in neu-
roblastoma PDXs grown in NSGmice (D). Mouse CD45-expressing lymphoid immune
cells in neuroblastoma PDXs grown in athymic nude mice, exempliﬁed by PDX #2
(E). Scale bar: 50 μm for A–C, E and 150 μm for D.
Fig. 2. Cancer-associated ﬁbroblasts (CAFs) contribute to neuroblastoma PDX stroma. Spindle-shaped CAFs expressing mouse/human vimentin in neuroblastoma PDXs,
exempliﬁed by PDX #3 (A). Vimentin-expressing human CAFs in a patient sample (B). Expression of mouse/human vimentin, α-smooth muscle actin, and lack of human-
speciﬁc vimentin in consecutive sections of PDX #3 (C). Scale bar: 30 μm for A, B and 200 μm for C.
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and also several huCD31+ cells in the 1st in vivo generation PDXs
#4 and #5. These huCD31+ cells had a thin and elongated mor-
phology and delineated blood vessels, demonstrating their
endothelial nature (Fig. 3C). Intratumoural human endothelial cells
decreased signiﬁcantly after in vivo passage to secondary recipi-
ents. The other three PDXmodels (#1–3) lacked huCD31-expressing
cells.
Alpha-smooth muscle actin (α-SMA)-expressing pericytes/
smooth muscle cells supported the blood vessels in all ﬁve PDXs
(Fig. 3D). We further analysed lymphatic vessel distribution in neu-
roblastoma PDXs using the mouse-speciﬁc LYVE-1 antibody, which
binds to hyaluronan receptors on lymphatic vessel walls [25]. Nu-
merous LYVE-1 positive lymphatic endothelial cells were observed
in athymic nude mice carrying cultured PDX cell-derived tumours
(Fig. 3E). The central regions of PDXs mostly contained collapsed
lymphatic vessels, while the peripheral parts of the tumours con-
tained larger lymph vessels with open lumina. Therewas no evidence
of lymphatic vessels in tumour-bearing NSGmice (data not shown).
The ECM composition of neuroblastoma PDXs resembles that of
aggressive patient tumours
The ECM of aggressive human neuroblastomas contains
abundant reticulin ﬁbres and a few collagen type I ﬁbres and gly-
cosaminoglycans [24]. Similarly, reticulin ﬁbres, collagen type I ﬁbres
restricted to blood vessels, and glycosaminoglycans were found in
PDXs (Fig. 4, Supplementary Table S3B). Thus, the ECM of neuro-
blastoma PDXs reﬂects the ECM proﬁle of aggressive human
neuroblastomas.
Distribution of stromal cells at metastatic sites
Neuroblastoma PDXs #1–3 have been shown tometastasise spon-
taneously to distant organs [9]. Here, we investigated the stromal
cell composition in metastatic liver lesions from PDXs #1–3. NCAM,
which is expressed by virtually all neuroblastoma PDX cells [9], was
used to identify metastatic neuroblastoma cells in the liver. The high
density of NCAM-expressing cells without signiﬁcant stroma sug-
gested that stroma was less abundant in metastatic liver lesions
compared to primary tumours (Fig. 5A). Indeed, metastatic lesions
only contained a few CD34-expressing endothelial cells (Fig. 5B),
α-SMA-expressing pericytes (Fig. 5C), and vimentin-expressing CAFs
(Fig. 5D).
Orthotopic neuroblastomas derived from cultured PDX cells retain
microenvironmental hallmarks
As shown above, neuroblastomas established by orthotopic in-
jection of cultured PDX cells into athymic nude mice contain mouse
CD45+ lymphoid cells (Fig. 1E) andmouse lymphatic vessels (Fig. 3E).
Further analysis of these tumours showed that they also retained
the other important TME hallmarks with rich vascularisation, peri-
cyte coverage, CAFs, and TAM inﬁltration (Supplementary Fig. S3).
Fig. 3. Neuroblastoma PDXs retain the vascular proﬁle of patient tumours. Mouse CD34+ tumour endothelial cells in PDX #4 (A). Human CD31+ endothelial cells in a
patient sample (B). Patient-derived human CD31+ endothelial cells in PDX #4 (C). Alpha-smooth muscle actin-expressing pericytes in PDXs, exempliﬁed by PDX #1 (D).
Intratumoural LYVE-1-expressing lymphatic vessels in a PDX grown in an athymic nude mouse, exempliﬁed by PDX #2 (E). Scale bar: 150 μm for A, B and 70 μm for C–E.
Fig. 4. Neuroblastoma PDXs resemble extracellular matrix components of ag-
gressive patient tumours. Reticulin ﬁbres in a high-risk patient tumour and in PDX
#1 visualised with Gomori staining (A). Thick bundles of perivascular type I colla-
gen ﬁbres (Masson’s trichrome, blue, B), and glycosaminoglycans (Alcian blue, light
blue, C) in a high-risk patient tumour and in PDX #2. Scale bar: 100 μm for A, B and
50 μm for C. (For interpretation of the references to colour in this ﬁgure legend, the
reader is referred to the web version of this article.)
Fig. 5. The tumour microenvironment of neuroblastoma metastases. Neuroblastoma PDX liver metastasis identiﬁed by NCAM expression (A). CD34+ mouse endothelial
cells (B), α-smooth muscle actin-expressing pericytes (C), and vimentin-expressing CAFs (D) in a neuroblastoma PDX liver metastasis. Scale bar: 130 μm in A and 50 μm in
B–D.
387N. Braekeveldt et al./Cancer Letters 375 (2016) 384–389
Integrated overview of tumour and stromal cells in neuroblastoma
PDXs
Finally, a multi-marker IHC approach was used to provide a single
composite image of seven different cell types in a neuroblastoma
PDX grown in an athymic nude mouse. Antibodies against mouse
α-SMA, mouse vimentin, mouse F4/80, mouse CD45, NCAM, CD34,
and LYVE-1 were used. Single antibody staining of these markers
is presented in Supplementary Fig. S1 and Figs. 1–4. Neuroblas-
toma PDXs contained large areas of densely packed NCAM+ tumour
cells with only single scattered stromal cells. Areas with a high
density of stromal cells were heterogeneous in PDXs and were often
located in peripheral parts of the tumour (Fig. 6). Using automatic
image-based quantitative analysis of a stroma-rich area, we esti-
mated the relative amounts of the different cell types (excluding
blood and lymphatic vessels; see Fig. 6). However, although indic-
ative of composite cell numbers, the automatic analysis could
potentially overestimate or underestimate the actual cell numbers
due to cell fragmentation or clustering in the images.
Discussion
Patient-derived xenografts (PDXs) are promising models for on-
cology preclinical drug testing because they are more predictive of
clinical outcome than conventional cell line-derived xenografts
[3,4,6]. We recently established a set of invasive and metastasising
neuroblastoma orthotopic PDXs containing tumour cells that re-
tained the genotypes and phenotypes of their corresponding patient
tumours [9]. Here, we established two additional neuroblastoma or-
thotopic PDX models: an MYCN-ampliﬁed PDX (#4) derived from
a stage III tumour with minimal metastatic spread and a meta-
static PDX (#5) derived from a non-MYCN-ampliﬁed stage IV tumour.
Interestingly, the PDX established from the stage III tumour did not
metastasise to the same extent as PDXs established from stage IV
tumours, thus closely mimicking this important clinical feature of
the tumour from which it was derived. Neuroblastoma PDXs were
found to contain rich blood vessel vascularisation, pericyte coverage,
TAMs, CAFs, and ECM components resembling the TME hallmarks
of aggressive neuroblastomas. In addition, lymphoid cells and lym-
phatic vessels were present in PDXs grown in athymic nude mice
but not in NSG mice. Two neuroblastoma PDX models contained
patient-derived tumour endothelial cells that formed tumour vas-
culature; however, the human stroma in these tumours was replaced
by mouse stroma during in vivo passaging. The distant tumour me-
tastases also contained TME hallmarks but to a lesser extent than
the primary tumours.
The presence of inﬁltrating TAMs in PDXs is in agreement with
the positive association of TAMs with the metastatic phenotype in
neuroblastoma patients [18]. The blood and lymphatic vascularisation
in neuroblastoma PDXs resembled the vascular proﬁle of clinical neu-
roblastomas [16,26]. The presence of collapsed lymphatic vessels
in central regions and larger lymphatic vessels in the periphery was
also consistent with the histopathological ﬁndings of clinical neu-
roblastomas [26]. The observation that the majority of stromal cells
in PDXs were CAFs, either scattered among tumour cells or as thick
bands of ﬁbrous stroma, was another striking similarity with clin-
ical samples [20]. However, the number of PDX stromal cells was
generally lower than in their corresponding patient tumours. Fur-
thermore, the function of murine stroma in PDXs remains largely
unknown. Some stroma-derived growth factors such as TNF may
not be cross-reactive between species [27], and it will be impor-
tant to clarify the functional signiﬁcance of murine stroma in
treatment responses and resistance in neuroblastoma PDXs.
The ﬁnding that patient-derived tumour endothelial cells can
form tumour vasculature opens up the possibility of studying and
targeting human neuroblastoma–tumour vasculature interactions
in vivo. However, since mouse endothelium replaced human vessels
after two passages in vivo, it will be important to develop methods
that increase the survival and integration of human TME compo-
nents in PDXs, especially when testing species-speciﬁc anti-
cancer compounds that target the tumour stroma. One possibility
would be to co-inject human stromal components (e.g., human en-
dothelial cells or mesenchymal stem cells [28]) with patient-
derived tumour cells. While co-engraftment of patient-derived
endothelial cells is in agreement with ﬁndings from prostate cancer
primary xenografts [29], the absence of patient-derived immune cells
in our PDXs differs from the ﬁndings in other PDX models [30,31].
There were also differences between athymic nude mice (with
defective T cell function) and severely immunodeﬁcient NSG mice
(lacking functional T-, B-, and NK cells), which created different TMEs.
Neuroblastoma PDXs in nude mice contained mouse intratumoural
lymphatic vessels and mouse CD45+ lymphoid cells in the perivas-
cular niche while NSG mice lacked these components. Given the
important role of lymphoid cells and lymphatic vessels in tumour
progression and metastasis [32,33], these differences must be con-
sideredwhen designing preclinical drug testing protocols using PDXs.
The lack of a proper immune system in immunodeﬁcient mice is,
of course, a limitation for the development of immunotherapies;
however, reconstitution of the human immune system in immu-
nodeﬁcient mice could make PDXs suitable for this application
[34–37].
In conclusion, neuroblastoma PDXs retain clinically important
TME hallmarks of aggressive and metastatic clinical neuroblasto-
mas including rich tumour blood and lymphatic vascularisation,
pericyte coverage, TAM and lymphoid cell inﬁltration, CAFs, and ECM
components. Patient-derived endothelial cells have the capacity to
form tumour blood vessels but murine stroma largely replaces the
human TME; therefore, strategies to faithfully reconstitute the human
Fig. 6. Integrated overview of tumour and stromal cells in a neuroblastoma or-
thotopic PDX.Multi-composite image revealing an integrated view of the PDX tumour
microenvironment and the well retained structural and cellular complexity similar
to the patient tumour. The upper panel shows a stroma-poor region with densely
packed NCAM+ neuroblastoma cells admixed with single scattered stromal cells. Rel-
ative numbers of the different cell types are shown in the upper panel. The magniﬁed
peripheral part of the tumour (lower panel) shows a stroma-rich region with few
NCAM-positive tumour cells and a large number of several different stromal cell types.
Scale bar is 150 μm in the upper panel and 50 μm in the lower panel. (For inter-
pretation of the references to colour in this ﬁgure legend, the reader is referred to
the web version of this article.)
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TME in PDXs might be necessary to further improve these models
for human tumour–TME interaction studies in vivo. Many of the TME
components found in neuroblastoma PDXs are implicated as crucial
mediators of tumour growth, metastasis, and therapeutic re-
sponses and resistance [10–12,18,32,33]. Our ﬁndings further support
the use of orthotopic neuroblastoma PDXs as clinically relevant
models for drug testing of metastatic neuroblastoma.
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